Carbon Monoxide Poisoning: The Weaver Trial and Why CO Is a Core HBOT Indication
A landmark 2002 NEJM trial reported fewer cognitive problems after HBOT for acute carbon monoxide poisoning. The wider evidence is mixed, but CO remains a core emergency indication.
A common and dangerous exposure
Carbon monoxide is a colorless, odorless gas produced whenever fuel is burned, from furnaces and gas ranges to cars and portable generators. Because it cannot be seen or smelled and its symptoms are vague, people can be seriously poisoned before they realize it. The U.S. Centers for Disease Control and Prevention reports that, in the United States, more than 400 people die each year from unintentional carbon monoxide poisoning not linked to fires, over 100,000 visit an emergency department, and more than 14,000 are hospitalized.
Early symptoms are easy to miss because they resemble other illnesses. The CDC describes headache, dizziness, weakness, nausea, confusion, and chest pain, and notes that people who are asleep or intoxicated can die before ever developing symptoms. This is why carbon monoxide detectors in the home are emphasized as a first line of protection.
One of the most feared consequences is delayed cognitive damage, which can appear weeks after the exposure. That risk is a large part of why hyperbaric oxygen has been studied and used in acute CO poisoning.
The Weaver trial
The most-cited study is the randomized, double-blind trial by Weaver and colleagues, published in the New England Journal of Medicine in 2002. It enrolled 152 patients with acute carbon monoxide poisoning, who received either three hyperbaric oxygen sessions within the first 24 hours or normobaric oxygen. The first hyperbaric session used a pressure of 3 atmospheres, followed by two sessions at 2 atmospheres.
At six weeks, cognitive problems were less frequent in the hyperbaric group, at 25 percent, compared with about 46 percent in the normobaric-oxygen group. The trial was stopped early at a planned interim analysis because the hyperbaric treatment was judged effective, and the advantage was still present at 12 months.
Why the evidence is still debated
Despite that result, the wider literature is not unanimous. Other randomized trials of HBOT for carbon monoxide poisoning have reached different conclusions, and systematic reviews have described the trials as conflicting and difficult to compare because they differ in design, timing, and how they measured outcomes. Commentators have pointed to specific limitations even within the Weaver trial, including follow-up rates and treatment delays.
The practical takeaway is that HBOT is an accepted and recognized option for serious acute CO poisoning, used within emergency protocols, rather than a settled guarantee of preventing every neurological complication. Carbon monoxide poisoning is one of the core emergency indications recognized by hyperbaric medicine bodies, but recognition reflects that it is a reasonable, evidence-informed option in serious cases, not that every study points the same way.
An emergency, treated as one
Carbon monoxide poisoning is treated in hospitals and emergency hyperbaric units, often with critical-care support, which is one reason larger room-style systems are used in this setting. Readers interested in how such multi-patient units differ from home devices can review an overview at multiplace chambers.
If you suspect carbon monoxide exposure, this is not a situation for self-treatment. Get to fresh air and seek emergency medical care immediately, and let emergency physicians decide whether hyperbaric oxygen is warranted.